Journal des biomarqueurs Libre accès

Abstrait

miRNAs Set Expression Profiles in Whole Blood During Prostate Cancer Patients Treatment

Katarzyna Monika Lamperska*, Piotr Milecki, Tomasz Kolenda, Anna Teresiak, Renata Blizniak, Aldona Kaczmarek, Ewa Leporowska, Wiktoria Suchorska, Julian Malicki, Agata Jurczyk-Reszelska and Michal Michalak

Background: Changes in expression profiles of the 5 selected miRNAs were analysed in a group of PC patients before treatment, after hormonotherapy and radiotherapy.

Objective: Whether the expression profiles of the miRNAs may be useful for monitoring prostate cancer treatment.

Methods: The initial study was carried out on 44 advanced prostate cancer patients and 41 healthy volunteers. The target group consisted of 39 PC patients. Blood for miRNA analysis was taken before treatment, after hormonotherapy and radiotherapy. The miRNAs were analysed by real-time PCR, followed by statistical analysis.

Results: For the target group, the statistically significant differences in the expression level were found after radiotherapy: for miR-21 only in the group of patients above the cut-off value designed in the preliminary study (p=0.0369) and miR-100 for the whole group (p=0.0413) and for the above cut-off value group (p=0.0140). The differences between the levels of each miRNA between the high and low expression groups were statistically significant. The designed groups were stable during treatment. Inclusion to the high and low expression group levels did not influence the treatment result.

Conclusion: The miRNAs studied in this work could not serve as biomarkers for the effectiveness of therapy for prostate cancer patients.